您当前的位置：
首页 >
文章列表页 >
Cost-utility analysis of amivantamab combined with lazertinib in the first-line treatment of EGFR-mutated advanced NSCLC
更新时间：2026-03-10

    • Cost-utility analysis of amivantamab combined with lazertinib in the first-line treatment of EGFR-mutated advanced NSCLC

    • “From the perspective of China's healthcare system, experts have evaluated the economic feasibility of the combination therapy of bevacizumab and lanzetinib for first-line treatment of EGFR mutant advanced non-small cell lung cancer. The results show that this regimen is not economical at the current price and needs to be significantly reduced to alleviate the medication burden on patients.”
    • ZHONGGUO YAOFANG   Vol. 37, Issue 5, Pages: 633-638(2026)

    • DOI：10.6039/j.issn.1001-0408.2026.05.14    

      CLC： R956;R979.1

    • Received：22 October 2025，

      Revised：2026-03-02，

      Accepted：02 March 2026，

      Published：15 March 2026

    移动端阅览

  • LIU Ran,GAO Shengnan,ZHANG Yuxi,et al.Cost-utility analysis of amivantamab combined with lazertinib in the first-line treatment of EGFR-mutated advanced NSCLC[J].ZHONGGUO YAOFANG,2026,37(05):633-638. DOI： 10.6039/j.issn.1001-0408.2026.05.14.

  •  
  •  

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Economic evaluation of NALIRIFOX regimen for first-line treatment of metastatic pancreatic cancer
Pharmacoeconomic evaluation of durvalumab combined with chemotherapy as first-line therapy for advanced biliary tract cancer
Pharmacoeconomic evaluation of penpulimab in first-line treatment of advanced squamous non-small-cell lung cancer
Pharmacoeconomic evaluation of iruplinalkib therapy for advanced ALK-positive non-small cell lung cancer
Cost-effectiveness analysis of toripalimab combined with paclitaxel in the treatment of metastatic or recurrent triple-negative breast cancer

Related Author

WANG Mingxia
JIA Caifeng
HU Dongxue
GAO Han
FENG Rui
SUN Xiaoli
SHAN Bin
LIANG Ping

Related Institution

Dept. of Pharmacy， the Fourth Hospital of Hebei Medical University
Dept. of Clinical Pharmacology， the Fourth Hospital of Hebei Medical University
School of Health Emergency Management， Tianjin University
School of Pharmacy， Hebei Medical University
Dept. of Pharmacy， Hebei Children’s Hospital
0